Telix’s Pixclara approval adds to the momentum of tumor imaging tools aimed at improving treatment selection in brain cancer. By clearing the first FDA-approved FET-PET imaging agent for glioma, regulators are enabling a molecular imaging approach designed to distinguish recurrent or progressive tumors from therapy-related changes. The approval also extends Telix’s diagnostic footprint by making Pixclara the first US-approved PET radiopharmaceutical specifically targeting brain cancer with the 18F-FET tracer. The decision follows FDA requests for additional clinical evidence and supports a more standardized imaging workflow in neuro-oncology settings. For biotech developers, the signal is that payers and clinicians continue to value imaging endpoints and molecular specificity, not only therapeutics, for reducing diagnostic ambiguity in complex indications.